Causes, consequences, and cures for neuroinflammation mediated via the locus coeruleus: noradrenergic signaling system

Journal of Neurochemistry

Volumn 139, Issue , 2016, Pages 154-178

  Feinstein, Douglas L ^a,b   Kalinin, Sergey ^a,b   Braun, David ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; locus coeruleus; multiple sclerosis; neurotrophin; noradrenaline; tyrosine hydroxylase

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 5 FLUORO METHOXYIDAZOXAN; 7,8 DIHYDROXYFLAVONE; ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; ATOMOXETINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOL METHYLTRANSFERASE INHIBITOR; DESIPRAMINE; DROXIDOPA; DULOXETINE; FLUPAROXAN; IMIPRAMINE; LEVODOPA; LOFEPRAMINE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; PHENYLALANINE; REBOXETINE; SELEGILINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TETRACYCLIC ANTIDEPRESSANT AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; VINDEBURNOL; VINPOCETINE; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BEHAVIOR; BRAIN STEM INJURY; COGNITIVE DEFECT; DEPRESSION; DISEASE EXACERBATION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HUMAN; HYPERTENSION; LOCUS CERULEUS; MULTIPLE SCLEROSIS; NERVE CELL LESION; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC DISEASE; NEUROPROTECTION; NEUROTROPISM; NONHUMAN; NORADRENERGIC NERVE CELL; NORADRENERGIC SYSTEM; ORTHOSTATIC HYPOTENSION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; ANIMAL; BRAIN; INFLAMMATION; METABOLISM; NERVE CELL; NERVOUS SYSTEM DISEASES; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; SPINAL CORD;

ANIMALS; BRAIN; HUMANS; INFLAMMATION; LOCUS COERULEUS; NERVOUS SYSTEM DISEASES; NEURONS; NEUROPROTECTIVE AGENTS; NOREPINEPHRINE; SIGNAL TRANSDUCTION; SPINAL CORD;

EID: 84960539954     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13447     Document Type: Article

References (285)

1. Adeosun S. O., Hou X., Jiao Y. et al. (2012) Allopregnanolone reinstates tyrosine hydroxylase immunoreactive neurons and motor performance in an MPTP-lesioned mouse model of Parkinson's disease. PLoS ONE 7, e50040.
2. Adolfsson R., Gottfries C. G., Roos B. E. and Winblad B. (1979) Changes in the brain catecholamines in patients with dementia of Alzheimer type. Br. J. Psychiatry 135, 216–223.
3. Adori C., Gluck L., Barde S. et al. (2015) Critical role of somatostatin receptor 2 in the vulnerability of the central noradrenergic system: new aspects on Alzheimer's disease. Acta Neuropathol. 129, 541–563.
4. Arenas E. and Persson H. (1994) Neurotrophin-3 prevents the death of adult central noradrenergic neurons in vivo. Nature 367, 368–371.
5. Aston-Jones G. (2005) Brain structures and receptors involved in alertness. Sleep Med. 6(Suppl 1), S3–S7.
6. Attems J., Thal D. R. and Jellinger K. A. (2012) The relationship between subcortical tau pathology and Alzheimer's disease. Biochem. Soc. Trans. 40, 711–715.
7. Baker K. G., Tork I., Hornung J. P. and Halasz P. (1989) The human locus coeruleus complex: an immunohistochemical and three dimensional reconstruction study. Exp. Brain Res. 77, 257–270.
8. Bardou I., Kaercher R. M., Brothers H. M., Hopp S. C., Royer S. and Wenk G. L. (2014) Age and duration of inflammatory environment differentially affect the neuroimmune response and catecholaminergic neurons in the midbrain and brainstem. Neurobiol. Aging 35, 1065–1073.
9. Barkhatova V. P., Zavalishin I. A., Askarova L., Shavratskii V. and Demina E. G. (1998) Changes in neurotransmitters in multiple sclerosis. Neurosci. Behav. Physiol. 28, 341–344.
10. Barun B. (2013) Pathophysiological background and clinical characteristics of sleep disorders in multiple sclerosis. Clin. Neurol. Neurosurg. 115(Suppl 1), S82–S85.
11. Beheim-Schwarzbach D. (1952) Cell changes in the nucleus coeruleus in Parkinson syndrome. J. Nerv. Ment. Dis. 116, 619–632.
12. Benarroch E. E. (2009) The locus coeruleus norepinephrine system: functional organization and potential clinical significance. Neurology 73, 1699–1704.
13. Benson C. A., Wong G., Tenorio G., Baker G. B. and Kerr B. J. (2013) The MAO inhibitor phenelzine can improve functional outcomes in mice with established clinical signs in experimental autoimmune encephalomyelitis (EAE). Behav. Brain Res. 252, 302–311.
14. Berne-Fromell K., Fromell H., Lundkvist S. and Lundkvist P. (1987) Is multiple sclerosis the equivalent of Parkinson's disease for noradrenaline? Med. Hypotheses 23, 409–415.
15. Berridge C. W., Schmeichel B. E. and Espana R. A. (2012) Noradrenergic modulation of wakefulness/arousal. Sleep Med. Rev. 16, 187–197.
16. Bezin L., Marcel D., Desgeorges S., Pujol J. F. and Weissmann D. (2000) Singular subsets of locus coeruleus neurons may recover tyrosine hydroxylase phenotype transiently expressed during development. Brain Res. Mol. Brain Res. 76, 275–281.
17. Bialecka M., Klodowska-Duda G., Honczarenko K., Gawronska-Szklarz B., Opala G., Safranow K. and Drozdzik M. (2007) Polymorphisms of catechol-0-methyltransferase (COMT), monoamine oxidase B (MAOB), N-acetyltransferase 2 (NAT2) and cytochrome P450 2D6 (CYP2D6) gene in patients with early onset of Parkinson's disease. Parkinsonism Relat. Disord. 13, 224–229.
18. Bielau H., Brisch R., Bernard-Mittelstaedt J. et al. (2012) Immunohistochemical evidence for impaired nitric oxide signaling of the locus coeruleus in bipolar disorder. Brain Res. 1459, 91–99.
19. Birks J. and Flicker L. (2003) Selegiline for Alzheimer's disease. Cochrane Database Syst. Rev. 1, Cd000442.
20. Bondareff W., Mountjoy C. Q. and Roth M. (1981) Selective loss of neurones of origin of adrenergic projection to cerebral cortex (nucleus locus coeruleus) in senile dementia. Lancet 1, 783–784.
21. Bondareff W., Mountjoy C. Q. and Roth M. (1982) Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus coeruleus) in senile dementia. Neurology 32, 164–168.
22. Bondareff W., Mountjoy C. Q., Roth M., Rossor M. N., Iversen L. L., Reynolds G. P. and Hauser D. L. (1987) Neuronal degeneration in locus coeruleus and cortical correlates of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 1, 256–262.
23. Braak H. and Del T. K. (2012) Where, when, and in what form does sporadic Alzheimer's disease begin? Curr. Opin. Neurol. 25, 708–714.
24. Braak H., Thal D. R., Ghebremedhin E. and Del T. K. (2011) Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol. 70, 960–969.
25. Bracha H. S., Garcia-Rill E., Mrak R. E. and Skinner R. (2005) Postmortem locus coeruleus neuron count in three American veterans with probable or possible war-related PTSD. J. Neuropsy. Clin. Neurosci. 17, 503–509.
26. Braun D., Madrigal J. L. and Feinstein D. L. (2014) Noradrenergic regulation of glial activation: molecular mechanisms and therapeutic implications. Curr. Neuropharmacol. 12, 342–352.
27. Bruno V., Copani A., Besong G., Scoto G. and Nicoletti F. (2000) Neuroprotective activity of chemokines against N-methyl-D-aspartate or beta-amyloid-induced toxicity in culture. Eur. J. Pharmacol. 399, 117–121.
28. Budni J., Bellettini-Santos T., Mina F., Garcez M. L. and Zugno A. I. (2015) The involvement of BDNF, NGF and GDNF in aging and Alzheimer's disease. Aging Dis. 6, 331–341.
29. Cai Z. (2014) Monoamine oxidase inhibitors: promising therapeutic agents for Alzheimer's disease (Review). Mol. Med. Rep. 9, 1533–1541.
30. Cambon K., Dos-Santos C. R., Groc L., Carbon A., Weissmann D., Changeux J. P., Pujol J. F. and Granon S. (2010) Aggressive behavior during social interaction in mice is controlled by the modulation of tyrosine hydroxylase expression in the prefrontal cortex. Neuroscience 171, 840–851.
31. Chandley M. J., Szebeni K., Szebeni A., Crawford J., Stockmeier C. A., Turecki G., Miguel-Hidalgo J. J. and Ordway G. A. (2013) Gene expression deficits in pontine locus coeruleus astrocytes in men with major depressive disorder. J. Psychiatry Neurosci. 38, 276–284.
32. Chan-Palay V. and Asan E. (1989) Quantitation of catecholamine neurons in the locus coeruleus in human brains of normal young and older adults and in depression. J. Comp. Neurol. 287, 357–372.
33. Charalampopoulos I., Dermitzaki E., Vardouli L., Tsatsanis C., Stournaras C., Margioris A. N. and Gravanis A. (2005) Dehydroepiandrosterone sulfate and allopregnanolone directly stimulate catecholamine production via induction of tyrosine hydroxylase and secretion by affecting actin polymerization. Endocrinology 146, 3309–3318.
34. Chen Y., Peng Y., Che P. et al. (2014) alpha(2A) adrenergic receptor promotes amyloidogenesis through disrupting APP-SorLA interaction. Proc. Natl Acad. Sci. USA 111, 17296–17301.
35. Counts S. E. and Mufson E. J. (2010) Noradrenaline activation of neurotrophic pathways protects against neuronal amyloid toxicity. J. Neurochem. 113, 649–660.
36. Cryan J. F., O'Leary O. F., Jin S. H. et al. (2004) Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors. Proc. Natl Acad. Sci. USA 101, 8186–8191.
37. Cui Z. T., Zhang T. M., Su Z. H. and Yen W. W. (1988) Morphological changes in locus coeruleus of albino rats in relation to aging. Acta Anat. 131, 207–209.
38. Dang V., Medina B., Das D. et al. (2014) Formoterol, a long-acting beta2 adrenergic agonist, improves cognitive function and promotes dendritic complexity in a mouse model of Down syndrome. Biol. Psychiatry 75, 179–188.
39. Day J. S., O'Neill E., Cawley C., Aretz N. K., Kilroy D., Gibney S. M., Harkin A. and Connor T. J. (2014) Noradrenaline acting on astrocytic beta(2)-adrenoceptors induces neurite outgrowth in primary cortical neurons. Neuropharmacology 77, 234–248.
40. De Keyser J., Wilczak N., Leta R. and Streetland C. (1999) Astrocytes in multiple sclerosis lack beta-2 adrenergic receptors. Neurology 53, 1628–1633.
41. Dello Russo C., Boullerne A. I., Gavrilyuk V. and Feinstein D. L. (2004) Inhibition of microglial inflammatory responses by norepinephrine: effects on nitric oxide and interleukin-1beta production. J. Neuroinflammation 1, 9.
42. DeMattei M., Levi A. C. and Fariello R. G. (1986) Neuromelanic pigment in substantia nigra neurons of rats and dogs. Neurosci. Lett. 72, 37–42.
43. Devi L. and Ohno M. (2012) 7,8-dihydroxyflavone, a small-molecule TrkB agonist, reverses memory deficits and BACE1 elevation in a mouse model of Alzheimer's disease. Neuropsychopharmacology 37, 434–444.
44. Di Giovanni S., Eleuteri S., Paleologou K. E., Yin G., Zweckstetter M., Carrupt P. A. and Lashuel H. A. (2010) Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity. J. Biol. Chem. 285, 14941–14954.
45. Diniz B. S. and Teixeira A. L. (2011) Brain-derived neurotrophic factor and Alzheimer's disease: physiopathology and beyond. Neuromolecular Med. 13, 217–222.
46. Double K. L. (2012) Neuronal vulnerability in Parkinson's disease. Parkinsonism Relat. Disord. 18(Suppl 1), S52–S54.
47. Downs J. L., Dunn M. R., Borok E., Shanabrough M., Horvath T. L., Kohama S. G. and Urbanski H. F. (2007) Orexin neuronal changes in the locus coeruleus of the aging rhesus macaque. Neurobiol. Aging 28, 1286–1295.
48. Du X. and Hill R. A. (2015) 7,8-dihydroxyflavone as a pro-neurotrophic treatment for neurodevelopmental disorders. Neurochem. Int. 89, 170–180.
49. Eisenhofer G. and Finberg J. P. (1994) Different metabolism of norepinephrine and epinephrine by catechol-O-methyltransferase and monoamine oxidase in rats. J. Pharmacol. Exp. Ther. 268, 1242–1251.
50. Elstner M., Muller S. K., Leidolt L. et al. (2011) Neuromelanin, neurotransmitter status and brainstem location determine the differential vulnerability of catecholaminergic neurons to mitochondrial DNA deletions. Mol. Brain 4, 43.
51. Emilsson L., Saetre P., Balciuniene J., Castensson A., Cairns N. and Jazin E. E. (2002) Increased monoamine oxidase messenger RNA expression levels in frontal cortex of Alzheimer's disease patients. Neurosci. Lett. 326, 56–60.
52. Espay A. J., LeWitt P. A. and Kaufmann H. (2014) Norepinephrine deficiency in Parkinson's disease: the case for noradrenergic enhancement. Mov. Disord. 29, 1710–1719.
53. Eugenin E. A., D'Aversa T. G., Lopez L., Calderon T. M. and Berman J. W. (2003) MCP-1 (CCL2) protects human neurons and astrocytes from NMDA or HIV-tat-induced apoptosis. J. Neurochem. 85, 1299–1311.
54. von Euler U. S. (1945) A sympathomimetic pressor substance in animal organ extracts. Nature 156, 18–19.
55. Farmer P. and Pugin J. (2000) beta-adrenergic agonists exert their “anti-inflammatory” effects in monocytic cells through the IkappaB/NF-kappaB pathway. Am. J. Physiol. Lung Cell. Mol. Physiol. 279, L675–L682.
56. Feinstein D. L., Galea E. and Reis D. J. (1993) Norepinephrine suppresses inducible nitric oxide synthase activity in rat astroglial cultures. J. Neurochem. 60, 1945–1948.
57. Feinstein D. L., Galea E., Aquino D. A., Li G. C., Xu H. and Reis D. J. (1996) Heat shock protein 70 suppresses astroglial-inducible nitric-oxide synthase expression by decreasing NFkappaB activation. J. Biol. Chem. 271, 17724–17732.
58. Fernandez-de-las-Penas C., mbite-Quesada S., Ortiz-Gutierrez R., Ortega-Santiago R., Gil-Crujera A. and Caminero A. B. (2013) Catechol-O-methyltransferase Val158Met polymorphism (rs4680) is associated with pain in multiple sclerosis. J. Pain 14, 1719–1723.
59. Finberg J. P. (2014) Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release. Pharmacol. Ther. 143, 133–152.
60. Flierl M. A., Rittirsch D., Nadeau B. A., Sarma J. V., Day D. E., Lentsch A. B., Huber-Lang M. S. and Ward P. A. (2009) Upregulation of phagocyte-derived catecholamines augments the acute inflammatory response. PLoS ONE 4, e4414.
61. Follmer C. (2014) Monoamine oxidase and alpha-synuclein as targets in Parkinson's disease therapy. Expert Rev. Neurother. 14, 703–716.
62. Foote S. L., Bloom F. E. and Aston-Jones G. (1983) Nucleus locus coeruleus: new evidence of anatomical and physiological specificity. Physiol. Rev. 63, 844–914.
63. Fornai F., Giorgi F. S., Alessandri M. G., Giusiani M. and Corsini G. U. (1999) Effects of pretreatment with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) on methamphetamine pharmacokinetics and striatal dopamine losses. J. Neurochem. 72, 777–784.
64. Fornai F., di Poggio A. B., Pellegrini A., Ruggieri S. and Paparelli A. (2007) Noradrenaline in Parkinson's disease: from disease progression to current therapeutics. Curr. Med. Chem. 14, 2330–2334.
65. Forno L. S. (1966) Pathology of Parkinsonism: a preliminary report of 24 cases. J. Neurosurg. 24(Suppl. Part II), 266–271.
66. Forno L. S. and Alvord E. C. Jr (1971) The pathology of parkinsonism. Part I. Some new observations and correlations. Contem. Neurol. Ser. 8, 119–130.
67. Francis B. M., Yang J., Hajderi E., Brown M. E., Michalski B., McLaurin J., Fahnestock M. and Mount H. T. (2012) Reduced tissue levels of noradrenaline are associated with behavioral phenotypes of the TgCRND8 mouse model of Alzheimer's disease. Neuropsychopharmacology 37, 1934–1944.
68. Fritschy J. M. and Grzanna R. (1989) Immunohistochemical analysis of the neurotoxic effects of DSP-4 identifies two populations of noradrenergic axon terminals. Neuroscience 30, 181–197.
69. Fritschy J. M. and Grzanna R. (1991) Selective effects of DSP-4 on locus coeruleus axons: are there pharmacologically different types of noradrenergic axons in the central nervous system? Prog. Brain Res. 88, 257–268.
70. Frohman E. M., Vayuvegula B., Gupta S. and van den N. S. (1988) Norepinephrine inhibits gamma-interferon-induced major histocompatibility class II (Ia) antigen expression on cultured astrocytes via beta-2-adrenergic signal transduction mechanisms. Proc. Natl Acad. Sci. USA 85, 1292–1296.
71. Gaal L. and Molnar P. (1990) Effect of vinpocetine on noradrenergic neurons in rat locus coeruleus. Eur. J. Pharmacol. 187, 537–539.
72. Gadea M., Martinez-Bisbal M. C., Marti-Bonmati L., Espert R., Casanova B., Coret F. and Celda B. (2004) Spectroscopic axonal damage of the right locus coeruleus relates to selective attention impairment in early stage relapsing-remitting multiple sclerosis. Brain 127, 89–98.
73. Galea E. and Feinstein D. L. (1999) Regulation of the expression of the inflammatory nitric oxide synthase (NOS2) by cyclic AMP. FASEB J. 13, 2125–2137.
74. Galea E., Heneka M. T., Dello R. C. and Feinstein D. L. (2003) Intrinsic regulation of brain inflammatory responses. Cell. Mol. Neurobiol. 23, 625–635.
75. Gannon M., Che P., Chen Y., Jiao K., Roberson E. D. and Wang Q. (2015) Noradrenergic dysfunction in Alzheimer's disease. Front. Neurosci. 9, 220.
76. Gavrilyuk V., Horvath P., Weinberg G. and Feinstein D. L. (2001) A 27-bp region of the inducible nitric oxide synthase promoter regulates expression in glial cells. J. Neurochem. 78, 129–140.
77. Gavrilyuk V., Dello R. C., Heneka M. T., Pelligrino D., Weinberg G. and Feinstein D. L. (2002) Norepinephrine increases I kappa B alpha expression in astrocytes. J. Biol. Chem. 277, 29662–29668.
78. George S. A., Knox D., Curtis A. L., Aldridge J. W., Valentino R. J. and Liberzon I. (2013) Altered locus coeruleus-norepinephrine function following single prolonged stress. Eur. J. Neuorsci. 37, 901–909.
79. German D. C., Manaye K. F., White C. L., 3rd, et al. (1992) Disease-specific patterns of locus coeruleus cell loss. Ann. Neurol. 32, 667–676.
80. German D. C., Nelson O., Liang F., Liang C. J. and Games D. (2005) The PDAPP mouse model of Alzheimer's disease: locus coeruleus neuronal shrinkage. J. Comp. Neurol. 492, 469–476.
81. German D. C., Walker B. S., Manaye K., Smith W. K., Woodward D. J. and North A. J. (1988) The human locus coeruleus: computer reconstruction of cellular distribution. J. Neurosci. 8, 1776–1788.
82. Ginovart N., Marcel D., Bezin L., Gagne C., Pujol J. F. and Weissmann D. (1996) Tyrosine hydroxylase expression within Balb/C and C57black/6 mouse locus coeruleus. II. Quantitative study of the enzyme level. Brain Res. 719, 45–55.
83. Gliebus G. and Lippa C. F. (2007) The influence of beta-blockers on delayed memory function in people with cognitive impairment. Am. J. Alzheimers Dis. Other Demen. 22, 57–61.
84. Goldman G. and Coleman P. D. (1981) Neuron numbers in locus coeruleus do not change with age in Fisher 344 rat. Neurobiol. Aging 2, 33–36.
85. Goldstein D. S. (2006) L-dihydroxyphenylserine (L-DOPS): a norepinephrine prodrug. Cardiovasc. Drug Rev. 24, 189–203.
86. Grudzien A., Shaw P., Weintraub S., Bigio E., Mash D. C. and Mesulam M. M. (2007) Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer's disease. Neurobiol. Aging 28, 327–335.
87. Guerin D., Sacquet J., Mandairon N., Jourdan F. and Didier A. (2009) Early locus coeruleus degeneration and olfactory dysfunctions in Tg2576 mice. Neurobiol. Aging 30, 272–283.
88. Gustafson I., Westerberg E. and Wieloch T. (1990) Protection against ischemia-induced neuronal damage by the alpha 2-adrenoceptor antagonist idazoxan: influence of time of administration and possible mechanisms of action. J. Cereb. Blood Flow Metab. 10, 885–894.
89. Hammerschmidt T., Kummer M. P., Terwel D. et al. (2013) Selective loss of noradrenaline exacerbates early cognitive dysfunction and synaptic deficits in APP/PS1 mice. Biol. Psychiatry 73, 454–463.
90. Hashioka S., Klegeris A., Monji A., Kato T., Sawada M., McGeer P. L. and Kanba S. (2007) Antidepressants inhibit interferon-gamma-induced microglial production of IL-6 and nitric oxide. Exp. Neurol. 206, 33–42.
91. He Z., Sun X., Guo Z. and Zhang J. H. (2011) Expression and role of COMT in a rat subarachnoid hemorrhage model. Acta Neurochir. Suppl. 110, 181–187.
92. Heckman P. R., Wouters C. and Prickaerts J. (2015) Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer's disease: a translational overview. Curr. Pharm. Des. 21, 317–331.
93. Helkamaa T., Reenila I., Tuominen R. K., Soinila S., Vaananen A., Tilgmann C. and Rauhala P. (2007) Increased catechol-O-methyltransferase activity and protein expression in OX-42-positive cells in the substantia nigra after lipopolysaccharide microinfusion. Neurochem. Int. 51, 412–423.
94. Heneka M. T., Galea E., Gavriluyk V., Dumitrescu-Ozimek L., Daeschner J., O'Banion M. K., Weinberg G., Klockgether T. and Feinstein D. L. (2002) Noradrenergic depletion potentiates beta -amyloid-induced cortical inflammation: implications for Alzheimer's disease. J. Neurosci. 22, 2434–2442.
95. Heneka M. T., Gavrilyuk V., Landreth G. E., O'Banion M. K., Weinberg G. and Feinstein D. L. (2003) Noradrenergic depletion increases inflammatory responses in brain: effects on IkappaB and HSP70 expression. J. Neurochem. 85, 387–398.
96. Heneka M. T., Ramanathan M., Jacobs A. H. et al. (2006) Locus coeruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J. Neurosci. 26, 1343–1354.
97. Heneka M. T., Nadrigny F., Regen T. et al. (2010) Locus coeruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine. Proc. Natl Acad. Sci. USA 107, 6058–6063.
98. Hinojosa A. E., Garcia-Bueno B., Leza J. C. and Madrigal J. L. (2011) Regulation of CCL2/MCP-1 production in astrocytes by desipramine and atomoxetine: involvement of alpha2 adrenergic receptors. Brain Res. Bull. 86, 326–333.
99. Hinojosa A. E., Caso J. R., Garcia-Bueno B., Leza J. C. and Madrigal J. L. (2013) Dual effects of noradrenaline on astroglial production of chemokines and pro-inflammatory mediators. J. Neuroinflammation 10, 81.
100. Holm P. C., Rodriguez F. J., Kresse A., Canals J. M., Silos-Santiago I. and Arenas E. (2003) Crucial role of TrkB ligands in the survival and phenotypic differentiation of developing locus coeruleus noradrenergic neurons. Development 130, 3535–3545.
101. Huang G., Dragan M., Freeman D. and Wilson J. X. (2005) Activation of catechol-O-methyltransferase in astrocytes stimulates homocysteine synthesis and export to neurons. Glia 51, 47–55.
102. Hurko O., Boudonck K., Gonzales C., Hughes Z. A., Jacobsen J. S., Reinhart P. H. and Crowther D. (2010) Ablation of the locus coeruleus increases oxidative stress in tg-2576 transgenic but not wild-type mice. Int. J. Alzheimers Dis. 2010, 864625.
103. Iravani M. M., Sadeghian M., Rose S. and Jenner P. (2014) Loss of locus coeruleus noradrenergic neurons alters the inflammatory response to LPS in substantia nigra but does not affect nigral cell loss. J. Neural. Transm. 121, 1493–1505.
104. Ishida Y., Shirokawa T., Miyaishi O., Komatsu Y. and Isobe K. (2001) Age-dependent changes in noradrenergic innervations of the frontal cortex in F344 rats. Neurobiol. Aging 22, 283–286.
105. Ishii Y., Yamaizumi A., Kawakami A., Islam A., Choudhury M. E., Takahashi H., Yano H. and Tanaka J. (2015) Anti-inflammatory effects of noradrenaline on LPS-treated microglial cells: suppression of NFkappaB nuclear translocation and subsequent STAT1 phosphorylation. Neurochem. Int. 90, 56–66.
106. Itoi K., Ohara S. and Kobayashi K. (2013) Selective ablation of dopamine beta-hydroxylase neurons in the brain by immunotoxin-mediated neuronal targeting: new insights into brain catecholaminergic circuitry and catecholamine-related diseases. Adv. Pharmacol. 68, 155–166.
107. Iversen L. L., Rossor M. N., Reynolds G. P., Hills R., Roth M., Mountjoy C. Q., Foote S. L., Morrison J. H. and Bloom F. E. (1983) Loss of pigmented dopamine-beta-hydroxylase positive cells from locus coeruleus in senile dementia of Alzheimer's type. Neurosci. Lett. 39, 95–100.
108. Iwasaki Y., Negishi T., Inoue M., Tashiro T., Tabira T. and Kimura N. (2012) Sendai virus vector-mediated brain-derived neurotrophic factor expression ameliorates memory deficits and synaptic degeneration in a transgenic mouse model of Alzheimer's disease. J. Neurosci. Res. 90, 981–989.
109. Jardanhazi-Kurutz D., Kummer M. P., Terwel D., Vogel K., Dyrks T., Thiele A. and Heneka M. T. (2010) Induced LC degeneration in APP/PS1 transgenic mice accelerates early cerebral amyloidosis and cognitive deficits. Neurochem. Int. 57, 375–382.
110. Jardanhazi-Kurutz D., Kummer M. P., Terwel D., Vogel K., Thiele A. and Heneka M. T. (2011) Distinct adrenergic system changes and neuroinflammation in response to induced locus coeruleus degeneration in APP/PS1 transgenic mice. Neuroscience 176, 396–407.
111. Jeon K. I., Xu X., Aizawa T. et al. (2010) Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanism. Proc. Natl Acad. Sci. USA 107, 9795–9800.
112. Jhang K. A., Lee E. O., Kim H. S. and Chong Y. H. (2014) Norepinephrine provides short-term neuroprotection against Abeta1-42 by reducing oxidative stress independent of Nrf2 activation. Neurobiol. Aging 35, 2465–2473.
113. Kalinin S., Polak P. E., Madrigal J. L., Gavrilyuk V., Sharp A., Chauhan N., Marien M., Colpaert F. and Feinstein D. L. (2006) Beta-amyloid-dependent expression of NOS2 in neurons: prevention by an alpha2-adrenergic antagonist. Antioxid. Redox Signal. 8, 873–883.
114. Kalinin S., Gavrilyuk V., Polak P. E., Vasser R., Zhao J., Heneka M. T. and Feinstein D. L. (2007) Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimer's disease. Neurobiol. Aging 28, 1206–1214.
115. Kalinin S., Polak P. E., Lin S. X., Sakharkar A. J., Pandey S. C. and Feinstein D. L. (2012) The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer's disease. Neurobiol. Aging 33, 1651–1663.
116. Katsouri L., Vizcaychipi M. P., McArthur S., Harrison I., Suarez-Calvet M., Lleo A., Lloyd D. G., Ma D. and Sastre M. (2013) Prazosin, an alpha(1)-adrenoceptor antagonist, prevents memory deterioration in the APP23 transgenic mouse model of Alzheimer's disease. Neurobiol. Aging 34, 1105–1115.
117. Kawa L., Arborelius U. P., Yoshitake T., Kehr J., Hokfelt T., Risling M. and Agoston D. (2015) Neurotransmitter systems in a mild blast traumatic brain injury model: catecholamines and serotonin. J. Neurotrauma 32, 1190–1199.
118. Keating G. M. (2015) Droxidopa: a review of its use in symptomatic neurogenic orthostatic hypotension. Drugs 75, 197–206.
119. Khoruzhaia T. A. and Saakov B. A. (1975) Change in monoamine content and monoamine oxidase activity in brain structures during experimental allergic encephalomyelitis. Biull. Eksp. Biol. Med. 79, 80–82.
120. Kong Y., Ruan L., Qian L., Liu X. and Le Y. (2010) Norepinephrine promotes microglia to uptake and degrade amyloid beta peptide through upregulation of mouse formyl peptide receptor 2 and induction of insulin-degrading enzyme. J. Neurosci. 30, 11848–11857.
121. Konkol R. J., Wesselmann U., Karpus W. J., Leo G. L., Killen J. A. and Roerig D. L. (1990) Suppression of clinical weakness in experimental autoimmune encephalomyelitis associated with weight changes, and post-decapitation convulsions after intracisternal-ventricular administration of 6-hydroxydopamine. J. Neuroimmunol. 26, 25–34.
122. Krenger W., Honegger C. G., Feurer C. and Cammisuli S. (1986) Changes of neurotransmitter systems in chronic relapsing experimental allergic encephalomyelitis in rat brain and spinal cord. J. Neurochem. 47, 1247–1254.
123. Kubis N., Faucheux B. A., Ransmayr G. et al. (2000) Preservation of midbrain catecholaminergic neurons in very old human subjects. Brain 123(), 366–373.
124. Kummer M. P., Hammerschmidt T., Martinez A. et al. (2014) Ear2 deletion causes early memory and learning deficits in APP/PS1 mice. J. Neurosci. 34, 8845–8854.
125. Labatut R., Richard F., Milne B., Quintin L., Lecestre D. and Pujol J. F. (1988) Long-term effects of RU24722 on tyrosine hydroxylase of the rat brain. J. Neurochem. 51, 1367–1374.
126. Leonard J. P., MacKenzie F. J., Patel H. A. and Cuzner M. L. (1991) Hypothalamic noradrenergic pathways exert an influence on neuroendocrine and clinical status in experimental autoimmune encephalomyelitis. Brain Behav. Immun. 5, 328–338.
127. Leslie F. M., Loughlin S. E., Sternberg D. B., McGaugh J. L., Young L. E. and Zornetzer S. F. (1985) Noradrenergic changes and memory loss in aged mice. Brain Res. 359, 292–299.
128. Li L., Cheung T., Chen J. and Herrup K. (2011) A comparative study of five mouse models of Alzheimer's disease: cell cycle events reveal new insights into neurons at risk for death. Int. J. Alzheimers Dis. 2011, 171464.
129. Li M., Yao W., Li S. and Xi J. (2015) Norepinephrine induces the expression of interleukin-6 via beta-adrenoreceptor-NAD(P)H oxidase system -NF-kappaB dependent signal pathway in U937 macrophages. Biochem. Biophys. Res. Commun. 460, 1029–1034.
130. Linker R. A., Lee D. H., Demir S. et al. (2010) Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis. Brain 133, 2248–2263.
131. Liu X., Ye K. and Weinshenker D. (2015) Norepinephrine protects against amyloid-beta toxicity via TrkB. J. Alzheimers Dis. 44, 251–260.
132. Lockrow J., Boger H., Gerhardt G., Aston-Jones G., Bachman D. and Granholm A. C. (2011) A noradrenergic lesion exacerbates neurodegeneration in a Down syndrome mouse model. J. Alzheimers Dis. 23, 471–489.
133. Loder C., Allawi J. and Horrobin D. F. (2002) Treatment of multiple sclerosis with lofepramine, L-phenylalanine and vitamin B(12): mechanism of action and clinical importance: roles of the locus coeruleus and central noradrenergic systems. Med. Hypotheses 59, 594–602.
134. Loop T., Bross T., Humar M., Hoetzel A., Schmidt R., Pahl H. L., Geiger K. K. and Pannen B. H. (2004) Dobutamine inhibits phorbol-myristate-acetate-induced activation of nuclear factor-kappaB in human T lymphocytes in vitro. Anest. Analg. 99, 1508–1515; table of contents.
135. Loughlin S. E., Foote S. L. and Grzanna R. (1986) Efferent projections of nucleus locus coeruleus: morphologic subpopulations have different efferent targets. Neuroscience 18, 307–319.
136. Luan Z., Saito Y., Miyata H., Ohama E., Ninomiya H. and Ohno K. (2008) Brainstem neuropathology in a mouse model of Niemann-Pick disease type C. J. Neurol. Sci. 268, 108–116.
137. Luellen B. A., Bianco L. E., Schneider L. M. and Andrews A. M. (2007) Reduced brain-derived neurotrophic factor is associated with a loss of serotonergic innervation in the hippocampus of aging mice. Genes Brain Behav. 6, 482–490.
138. Luhder F., Gold R., Flugel A. and Linker R. A. (2013) Brain-derived neurotrophic factor in neuroimmunology: lessons learned from multiple sclerosis patients and experimental autoimmune encephalomyelitis models. Arch. Immunol. Ther. Exp. 61, 95–105.
139. Mackenzie F. J., Leonard J. P. and Cuzner M. L. (1989) Changes in lymphocyte beta-adrenergic receptor density and noradrenaline content of the spleen are early indicators of immune reactivity in acute experimental allergic encephalomyelitis in the Lewis rat. J. Neuroimmunol. 23, 93–100.
140. Madrigal J. L., Feinstein D. L. and Dello R. C. (2005) Norepinephrine protects cortical neurons against microglial-induced cell death. J. Neurosci. Res. 81, 390–396.
141. Madrigal J. L., Dello R. C., Gavrilyuk V. and Feinstein D. L. (2006) Effects of noradrenaline on neuronal NOS2 expression and viability. Antioxid. Redox Signal. 8, 885–892.
142. Madrigal J. L., Kalinin S., Richardson J. C. and Feinstein D. L. (2007) Neuroprotective actions of noradrenaline: effects on glutathione synthesis and activation of peroxisome proliferator activated receptor delta. J. Neurochem. 103, 2092–2101.
143. Madrigal J. L., Leza J. C., Polak P., Kalinin S. and Feinstein D. L. (2009) Astrocyte-derived MCP-1 mediates neuroprotective effects of noradrenaline. J. Neurosci. 29, 263–267.
144. Makar T. K., Trisler D., Sura K. T., Sultana S., Patel N. and Bever C. T. (2008) Brain derived neurotrophic factor treatment reduces inflammation and apoptosis in experimental allergic encephalomyelitis. J. Neurol. Sci. 270, 70–76.
145. Malberg J. E., Eisch A. J., Nestler E. J. and Duman R. S. (2000) Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci. 20, 9104–9110.
146. Mann D. M. (1983) The locus coeruleus and its possible role in ageing and degenerative disease of the human central nervous system. Mech. Ageing Dev. 23, 73–94.
147. Mann D. M., Lincoln J., Yates P. O., Stamp J. E. and Toper S. (1980) Changes in the monoamine containing neurones of the human CNS in senile dementia. Br. J. Psychiatry 136, 533–541.
148. Mann D. M., Yates P. O. and Hawkes J. (1982) The noradrenergic system in Alzheimer and multi-infarct dementias. J. Neurol. Neurosurg. Psychiatry 45, 113–119.
149. Marcel D., Raison S., Bezin L., Pujol J. F. and Weissmann D. (1998) Plasticity of tyrosine hydroxylase gene expression within BALB/C and C57Black/6 mouse locus coeruleus. Neurosci. Lett. 242, 77–80.
150. Marien M. R., Colpaert F. C. and Rosenquist A. C. (2004) Noradrenergic mechanisms in neurodegenerative diseases: a theory. Brain Res. Brain Res. Rev. 45, 38–78.
151. Markianos M., Koutsis G., Evangelopoulos M. E., Mandellos D., Karahalios G. and Sfagos C. (2009) Relationship of CSF neurotransmitter metabolite levels to disease severity and disability in multiple sclerosis. J. Neurochem. 108, 158–164.
152. Martel J., Chopin P., Colpaert F. and Marien M. (1998) Neuroprotective effects of the alpha2-adrenoceptor antagonists, (+)-efaroxan and (+/-)-idazoxan, against quinolinic acid-induced lesions of the rat striatum. Exp. Neurol. 154, 595–601.
153. Matsunaga W., Shirokawa T. and Isobe K. (2004) BDNF is necessary for maintenance of noradrenergic innervations in the aged rat brain. Neurobiol. Aging 25, 341–348.
154. McNamee E. N., Griffin E. W., Ryan K. M., Ryan K. J., Heffernan S., Harkin A. and Connor T. J. (2010a) Noradrenaline acting at beta-adrenoceptors induces expression of IL-1beta and its negative regulators IL-1ra and IL-1RII, and drives an overall anti-inflammatory phenotype in rat cortex. Neuropharmacology 59, 37–48.
155. McNamee E. N., Ryan K. M., Griffin E. W., Gonzalez-Reyes R. E., Ryan K. J., Harkin A. and Connor T. J. (2010b) Noradrenaline acting at central beta-adrenoceptors induces interleukin-10 and suppressor of cytokine signaling-3 expression in rat brain: implications for neurodegeneration. Brain Behav. Immun. 24, 660–671.
156. McNamee E. N., Ryan K. M., Kilroy D. and Connor T. J. (2010c) Noradrenaline induces IL-1ra and IL-1 type II receptor expression in primary glial cells and protects against IL-1beta-induced neurotoxicity. Eur. J. Pharmacol. 626, 219–228.
157. Medina A. E. (2011) Therapeutic utility of phosphodiesterase type I inhibitors in neurological conditions. Front. Neurosci. 5, 21.
158. Mehler M. F. and Purpura D. P. (2009) Autism, fever, epigenetics and the locus coeruleus. Brain Res, Rev. 59, 388–392.
159. Miller M. A., Kolb P. E., Leverenz J. B., Peskind E. R. and Raskind M. A. (1999) Preservation of noradrenergic neurons in the locus coeruleus that coexpress galanin mRNA in Alzheimer's disease. J. Neurochem. 73, 2028–2036.
160. Minghetti L., Nicolini A., Polazzi E., Creminon C., Maclouf J. and Levi G. (1997) Inducible nitric oxide synthase expression in activated rat microglial cultures is downregulated by exogenous prostaglandin E2 and by cyclooxygenase inhibitors. Glia 19, 152–160.
161. Mohs R. C., Shiovitz T. M., Tariot P. N., Porsteinsson A. P., Baker K. D. and Feldman P. D. (2009) Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study. Am. J. Geriatr. Psychiatry 17, 752–759.
162. Mokhber N., Abdollahian E., Soltanifar A., Samadi R., Saghebi A., Haghighi M. B. and Azarpazhooh A. (2014) Comparison of sertraline, venlafaxine and desipramine effects on depression, cognition and the daily living activities in Alzheimer patients. Pharmacopsychiatry 47, 131–140.
163. Mouton P. R., Pakkenberg B., Gundersen H. J. and Price D. L. (1994) Absolute number and size of pigmented locus coeruleus neurons in young and aged individuals. J. Chem. Neuroanat. 7, 185–190.
164. Mufson E. J., Kroin J. S., Sendera T. J. and Sobreviela T. (1999) Distribution and retrograde transport of trophic factors in the central nervous system: functional implications for the treatment of neurodegenerative diseases. Prog. Neurobiol. 57, 451–484.
165. Muller T. (2009) Levodopa/carbidopa and entacapone in the treatment of Parkinson's disease: efficacy, safety and patient preference. Patient Prefer. Adherence 3, 51–59.
166. Muller T., Kuhn W. and Przuntek H. (1993) Therapy with central active catechol-O-methyltransferase (COMT)-inhibitors: is addition of monoamine oxidase (MAO)-inhibitors necessary to slow progress of neurodegenerative disorders? J. Neural Transm. Gen. Sect. 92, 187–195.
167. Musgrave T., Benson C., Wong G., Browne I., Tenorio G., Rauw G., Baker G. B. and Kerr B. J. (2011) The MAO inhibitor phenelzine improves functional outcomes in mice with experimental autoimmune encephalomyelitis (EAE). Brain Behav. Immun. 25, 1677–1688.
168. Musiek E. S., Xiong D. D. and Holtzman D. M. (2015) Sleep, circadian rhythms, and the pathogenesis of Alzheimer disease. Exp. Mol. Med. 47, e148.
169. Myohanen T. T., Schendzielorz N. and Mannisto P. T. (2010) Distribution of catechol-O-methyltransferase (COMT) proteins and enzymatic activities in wild-type and soluble COMT deficient mice. J. Neurochem. 113, 1632–1643.
170. Nakai S., Matsunaga W., Ishida Y., Isobe K. and Shirokawa T. (2006) Effects of BDNF infusion on the axon terminals of locus coeruleus neurons of aging rats. Neurosci. Res. 54, 213–219.
171. Nakamura K., Ahmed M., Barr E., Leiden J. M. and Kang U. J. (2000) The localization and functional contribution of striatal aromatic L-amino acid decarboxylase to L-3,4-dihydroxyphenylalanine decarboxylation in rodent parkinsonian models. Cell Transplant. 9, 567–576.
172. Nevsimalova S. and Malinova V. (2015) Cataplexy and sleep disorders in Niemann-Pick type C disease. Curr. Neurol. Neurosci. Rep. 15, 522.
173. Nord M., Zsigmond P., Kullman A., Arstrand K. and Dizdar N. (2010) The effect of peripheral enzyme inhibitors on levodopa concentrations in blood and CSF. Mov. Disord. 25, 363–367.
174. Oakley H., Cole S. L., Logan S. et al. (2006) Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26, 10129–10140.
175. Ogunrin A. (2014) Effect of vinpocetine (cognitol) on cognitive performances of a nigerian population. Ann. Med. Health Sci. Res. 4, 654–661.
176. Ohm T. G., Busch C. and Bohl J. (1997) Unbiased estimation of neuronal numbers in the human nucleus coeruleus during aging. Neurobiol. Aging 18, 393–399.
177. Oikawa N., Ogino K., Masumoto T., Yamaguchi H. and Yanagisawa K. (2010) Gender effect on the accumulation of hyperphosphorylated tau in the brain of locus-coeruleus-injured APP-transgenic mouse. Neurosci. Lett. 468, 243–247.
178. O'Neil J. N., Mouton P. R., Tizabi Y., Ottinger M. A., Lei D. L., Ingram D. K. and Manaye K. F. (2007) Catecholaminergic neuronal loss in locus coeruleus of aged female dtg APP/PS1 mice. J. Chem. Neuroanat. 34, 102–107.
179. O'Sullivan J. B., Ryan K. M., Curtin N. M., Harkin A. and Connor T. J. (2009) Noradrenaline reuptake inhibitors limit neuroinflammation in rat cortex following a systemic inflammatory challenge: implications for depression and neurodegeneration. Int. J. Neuropsychopharmacol. 12, 687–699.
180. O'Sullivan J. B., Ryan K. M., Harkin A. and Connor T. J. (2010) Noradrenaline reuptake inhibitors inhibit expression of chemokines IP-10 and RANTES and cell adhesion molecules VCAM-1 and ICAM-1 in the CNS following a systemic inflammatory challenge. J. Neuroimmunol. 220, 34–42.
181. Pahan K., Namboodiri A. M., Sheikh F. G., Smith B. T. and Singh I. (1997) Increasing cAMP attenuates induction of inducible nitric-oxide synthase in rat primary astrocytes. J. Biol. Chem. 272, 7786–7791.
182. Palmer A. M. and DeKosky S. T. (1993) Monoamine neurons in aging and Alzheimer's disease. J. Neural Transm. Gen. Sect. 91, 135–159.
183. Pamphlett R. (2014) Uptake of environmental toxicants by the locus coeruleus: a potential trigger for neurodegenerative, demyelinating and psychiatric disorders. Med. Hypotheses 82, 97–104.
184. Pamphlett R. and Kum Jew. S. (2015) Different populations of human locus coeruleus neurons contain heavy metals or hyperphosphorylated Tau: implications for amyloid-beta and Tau pathology in Alzheimer's disease. J. Alzheimers Dis. 45, 437–447.
185. Patel N. J., Chen M. J. and Russo-Neustadt A. A. (2010) Norepinephrine and nitric oxide promote cell survival signaling in hippocampal neurons. Eur. J. Pharmacol. 633, 1–9.
186. Pazini A. M., Gomes G. M., Villarinho J. G., da Cunha C., Pinheiro F., Ferreira A. P., Mello C. F., Ferreira J. and Rubin M. A. (2013) Selegiline reverses abeta(2)(5)(-)(3)(5)-induced cognitive deficit in male mice. Neurochem. Res. 38, 2287–2294.
187. Perez L. P., Gonzalez R. S. and Lazaro E. B. (2015) Treatment of mood disorders in multiple sclerosis. Curr. Treat Options Neurol. 17, 323.
188. Perry E. K., Tomlinson B. E., Blessed G., Perry R. H., Cross A. J. and Crow T. J. (1981) Neuropathological and biochemical observations on the noradrenergic system in Alzheimer's disease. J. Neurol. Sci. 51, 279–287.
189. Phillips C., Fahimi A., Das D., Mojabi F. S., Ponnusamy R. and Salehi A. (2016) Noradrenergic system in Down syndrome and Alzheimer's disease a target for therapy. Curr. Alzheimer Res. 13, 68–83.
190. Pietrzak R. H., Gallezot J. D., Ding Y. S., Henry S., Potenza M. N., Southwick S. M., Krystal J. H., Carson R. E. and Neumeister A. (2013) Association of posttraumatic stress disorder with reduced in vivo norepinephrine transporter availability in the locus coeruleus. JAMA Psychiatry 70, 1199–1205.
191. Polak P. E., Kalinin S. and Feinstein D. L. (2011) Locus coeruleus damage and noradrenaline reductions in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain 134, 665–677.
192. Polak P. E., Kalinin S., Braun D., Sharp A., Lin S. X. and Feinstein D. L. (2012) The vincamine derivative vindeburnol provides benefit in a mouse model of multiple sclerosis: effects on the Locus coeruleus. J. Neurochem. 121, 206–216.
193. Polak P. E., Lin S. X., Pelligrino D. and Feinstein D. L. (2014) The blood-brain barrier-permeable catechol-O-methyltransferase inhibitor dinitrocatechol suppresses experimental autoimmune encephalomyelitis. J. Neuroimmunol. 276, 135–141.
194. Pugh P. L., Vidgeon-Hart M. P., Ashmeade T. et al. (2007) Repeated administration of the noradrenergic neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) modulates neuroinflammation and amyloid plaque load in mice bearing amyloid precursor protein and presenilin-1 mutant transgenes. J. Neuroinflammation 4, 8.
195. Puri B. K., Bydder G. M., Chaudhuri K. R., Al Saffar B. Y., Curati W. L., White S. J., Mitchell L., Hajnal J. V. and Horrobin D. F. (2001) MRI changes in multiple sclerosis following treatment with lofepramine and L-phenylalanine. NeuroReport 12, 1821–1824.
196. Rajda C., Bencsik K., Fuvesi J., Seres E., Vecsei L. and Bergquist J. (2006) The norepinephrine level is decreased in the lymphocytes of long-term interferon-beta-treated multiple sclerosis patients. Mult. Scler. 12, 265–270.
197. Redell J. B. and Dash P. K. (2007) Traumatic brain injury stimulates hippocampal catechol-O-methyl transferase expression in microglia. Neurosci. Lett. 413, 36–41.
198. Reeve A., Meagher M., Lax N., Simcox E., Hepplewhite P., Jaros E. and Turnbull D. (2013) The impact of pathogenic mitochondrial DNA mutations on substantia nigra neurons. J. Neurosci. 33, 10790–10801.
199. Remy S., Naveilhan P., Brachet P. and Neveu I. (2001) Differential regulation of GDNF, neurturin, and their receptors in primary cultures of rat glial cells. J. Neurosci. Res. 64, 242–251.
200. Rey N. L., Jardanhazi-Kurutz D., Terwel D., Kummer M. P., Jourdan F., Didier A. and Heneka M. T. (2012) Locus coeruleus degeneration exacerbates olfactory deficits in APP/PS1 transgenic mice. Neurobiol. Aging 33, 426.e1–11.
201. Richards S. S., Emsley C. L., Roberts J., Murray M. D., Hall K., Gao S. and Hendrie H. C. (2000) The association between vascular risk factor-mediating medications and cognition and dementia diagnosis in a community-based sample of African-Americans. J. Am. Geriatr. Soc. 48, 1035–1041.
202. Rintala J., Jaatinen P., Wei L., Sarviharju M., Eriksson P., Kiianmaa K. and Hervonen A. (1998) Lifelong ethanol consumption and loss of locus coeruleus neurons in AA and ANA rats. Alcohol 16, 243–248.
203. Rizk P., Salazar J., Raisman-Vozari R., Marien M., Ruberg M., Colpaert F. and Debeir T. (2006) The alpha2-adrenoceptor antagonist dexefaroxan enhances hippocampal neurogenesis by increasing the survival and differentiation of new granule cells. Neuropsychopharmacology 31, 1146–1157.
204. Robinson D. S. (1975) Changes in monoamine oxidase and monoamines with human development and aging. Fed. Proc. 34, 103–107.
205. Rommelfanger K. S. and Weinshenker D. (2007) Norepinephrine: the redheaded stepchild of Parkinson's disease. Biochem. Pharmacol. 74, 177–190.
206. Rommelfanger K. S., Edwards G. L., Freeman K. G., Liles L. C., Miller G. W. and Weinshenker D. (2007) Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice. Proc. Natl Acad. Sci. USA 104, 13804–13809.
207. Ross S. B. (1976) Long-term effects of N-2-chlorethyl-N-ethyl-2-bromobenzylamine hydrochloride on noradrenergic neurones in the rat brain and heart. Br. J. Pharmacol. 58, 521–527.
208. Ross S. B. and Stenfors C. (2015) DSP4, a selective neurotoxin for the locus coeruleus noradrenergic system. A review of its mode of action. Neurotox. Res. 27, 15–30.
209. Rossner S., Sastre M., Bourne K. and Lichtenthaler S. F. (2006) Transcriptional and translational regulation of BACE1 expression–implications for Alzheimer's disease. Prog. Neurobiol. 79, 95–111.
210. Roveti G. (1956) Inclusion bodies in substantia nigra cells and locus coeruleus in cases without Parkinson's syndrome, with a contribution to senile changes in these regions. Monatsschr. Psychiatr. Neurol. 132, 347–363.
211. Russo-Neustadt A., Beard R. C. and Cotman C. W. (1999) Exercise, antidepressant medications, and enhanced brain derived neurotrophic factor expression. Neuropsychopharmacology 21, 679–682.
212. Saarelainen T., Hendolin P., Lucas G. et al. (2003) Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects. J. Neurosci. 23, 349–357.
213. Salehi A., Faizi M., Colas D. et al. (2009) Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome. Sci. Transl. Med. 1, 7ra17.
214. Saragea M., Rotaru N., Negru T. and Vladutiu A. (1965) Monoamine oxidase and acetylcholinesterase activity in animals with experimental allergic encephalomyelitis. Nature 206, 306–307.
215. Scanzano A. and Cosentino M. (2015) Adrenergic regulation of innate immunity: a review. Front. Pharmacol. 6, 171.
216. Schlachetzki J. C., Fiebich B. L., Haake E., de Oliveira A. C., Candelario-Jalil E., Heneka M. T. and Hull M. (2010) Norepinephrine enhances the LPS-induced expression of COX-2 and secretion of PGE2 in primary rat microglia. J. Neuroinflammation 7, 2.
217. Schumacher M., Mattern C., Ghoumari A., Oudinet J. P., Liere P., Labombarda F., Sitruk-Ware R., De Nicola A. F. and Guennoun R. (2014) Revisiting the roles of progesterone and allopregnanolone in the nervous system: resurgence of the progesterone receptors. Prog. Neurobiol. 113, 6–39.
218. Schwarz L. A. and Luo L. (2015) Organization of the locus coeruleus-norepinephrine system. Curr. Biol. 25, R1051–R1056.
219. Scullion G. A., Kendall D. A., Marsden C. A., Sunter D. and Pardon M. C. (2011) Chronic treatment with the alpha2-adrenoceptor antagonist fluparoxan prevents age-related deficits in spatial working memory in APPxPS1 transgenic mice without altering beta-amyloid plaque load or astrocytosis. Neuropharmacology 60, 223–234.
220. Serretti A. and Olgiati P. (2012) Catechol-o-methyltransferase and Alzheimer's disease: a review of biological and genetic findings. CNS Neurol. Disord. Drug Targets 11, 299–305.
221. Shin M. H., Mavila N., Wang W. H., Vega A. S., Hall M. C. and Andrisani O. M. (2009) Time-dependent activation of Phox2a by the cyclic AMP pathway modulates onset and duration of p27Kip1 transcription. Mol. Cell. Biol. 29, 4878–4890.
222. Shin E., Rogers J. T., Devoto P., Bjorklund A. and Carta M. (2014) Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. Exp. Neurol. 257, 25–38.
223. Shores M. M., White S. S., Veith R. C. and Szot P. (1999) Tyrosine hydroxylase mRNA is increased in old age and norepinephrine uptake transporter mRNA is decreased in middle age in locus coeruleus of Brown-Norway rats. Brain Res. 826, 143–147.
224. Simonini M. V., Polak P. E., Sharp A., McGuire S., Galea E. and Feinstein D. L. (2010) Increasing CNS noradrenaline reduces EAE severity. J. Neuroimmune Pharmacol. 5, 252–259.
225. Singh C., Liu L., Wang J. M., Irwin R. W., Yao J., Chen S., Henry S., Thompson R. F. and Brinton R. D. (2012) Allopregnanolone restores hippocampal-dependent learning and memory and neural progenitor survival in aging 3xTgAD and nonTg mice. Neurobiol. Aging 33, 1493–1506.
226. Solaro C., Bergamaschi R., Rezzani C. et al. (2013) Duloxetine is effective in treating depression in multiple sclerosis patients: an open-label multicenter study. Clin. Neuropharmacol. 36, 114–116.
227. Srinivasan J. and Schmidt W. J. (2004) Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease. Behav. Brain Res. 151, 191–199.
228. Stefani A., Olivola E., Liguori C., Hainsworth A. H., Saviozzi V., Angileri G., D'Angelo V., Galati S. and Pierantozzi M. (2015) Catecholamine-based treatment in AD patients: expectations and delusions. Front. Aging Neurosci. 7, 67.
229. Sturrock R. R. and Rao K. A. (1985) A quantitative histological study of neuronal loss from the locus coeruleus of ageing mice. Neuropathol. Appl. Neurobiol. 11, 55–60.
230. Sun C., Ou X., Farley J. M., Stockmeier C., Bigler S., Brinton R. D. and Wang J. M. (2012) Allopregnanolone increases the number of dopaminergic neurons in substantia nigra of a triple transgenic mouse model of Alzheimer's disease. Curr. Alzheimer Res. 9, 473–480.
231. Suzumura A., Nakamuro T., Tamaru T. and Takayanagi T. (2000) Drop in relapse rate of MS by combination therapy of three different phosphodiesterase inhibitors. Mult. Scler. 6, 56–58.
232. Swanson L. W. (2014) Neuroanatomical terminology: a lexicon of classical origins and historical foundations. Oxford University Press, England.
233. Szabadi E. (2013) Functional neuroanatomy of the central noradrenergic system. J. Psychopharmacol. 27, 659–693.
234. Szabo C., Hasko G., Zingarelli B., Nemeth Z. H., Salzman A. L., Kvetan V., Pastores S. M. and Vizi E. S. (1997) Isoproterenol regulates tumour necrosis factor, interleukin-10, interleukin-6 and nitric oxide production and protects against the development of vascular hyporeactivity in endotoxaemia. Immunology 90, 95–100.
235. Szot P. (2012) Common factors among Alzheimer's disease, Parkinson's disease, and epilepsy: possible role of the noradrenergic nervous system. Epilepsia 53(Suppl 1), 61–66.
236. Szot P., Van Dam D., White S. S., Franklin A., Staufenbiel M. and De Deyn P. P. (2009) Age-dependent changes in noradrenergic locus coeruleus system in wild-type and APP23 transgenic mice. Neurosci. Lett. 463, 93–97.
237. Szot P., Miguelez C., White S. S., Franklin A., Sikkema C., Wilkinson C. W., Ugedo L. and Raskind M. A. (2010) A comprehensive analysis of the effect of DSP4 on the locus coeruleus noradrenergic system in the rat. Neuroscience 166, 279–291.
238. Tajouri L., Martin V., Gasparini C. et al. (2006) Genetic investigation of methylenetetrahydrofolate reductase (MTHFR) and catechol-O-methyl transferase (COMT) in multiple sclerosis. Brain Res. Bull. 69, 327–331.
239. Takeda N., Yamatodani A., Watanabe T. and Wada H. (1984) Effect of a new eburnamine derivative, RU 24722, on the turnover of monoamines in mouse brain: selective and reversible decrease of noradrenaline. Eur. J. Pharmacol. 106, 357–362.
240. Takehashi M., Tanaka S., Masliah E. and Ueda K. (2002) Association of monoamine oxidase A gene polymorphism with Alzheimer's disease and Lewy body variant. Neurosci. Lett. 327, 79–82.
241. Tatton W. G., Greenwood C. E., Verrier M. C., Holland D. P., Kwan M. M. and Biddle F. E. (1991) Different rates of age-related loss for four murine monoaminergic neuronal populations. Neurobiol. Aging 12, 543–556.
242. Timmers H. J., Deinum J., Wevers R. A. and Lenders J. W. (2004) Congenital dopamine-beta-hydroxylase deficiency in humans. Ann. N. Y. Acad. Sci. 1018, 520–523.
243. Tomlinson B. E., Irving D. and Blessed G. (1981) Cell loss in the locus coeruleus in senile dementia of Alzheimer type. J. Neurol. Sci. 49, 419–428.
244. Tong L., Balazs R., Thornton P. L. and Cotman C. W. (2004) Beta-amyloid peptide at sublethal concentrations downregulates brain-derived neurotrophic factor functions in cultured cortical neurons. J. Neurosci. 24, 6799–6809.
245. Traver S., Salthun-Lassalle B., Marien M., Hirsch E. C., Colpaert F. and Michel P. P. (2005) The neurotransmitter noradrenaline rescues septal cholinergic neurons in culture from degeneration caused by low-level oxidative stress. Mol. Pharmacol. 67, 1882–1891.
246. Tribl F., Arzberger T., Riederer P. and Gerlach M. (2007) Tyrosinase is not detected in human catecholaminergic neurons by immunohistochemistry and Western blot analysis. J. Neural Transm. Suppl. 72, 51–55.
247. Trillo L., Das D., Hsieh W. et al. (2013) Ascending monoaminergic systems alterations in Alzheimer's disease. translating basic science into clinical care. Neurosci. Biobehav. Rev. 37, 1363–1379.
248. Troadec J. D., Marien M., Darios F., Hartmann A., Ruberg M., Colpaert F. and Michel P. P. (2001) Noradrenaline provides long-term protection to dopaminergic neurons by reducing oxidative stress. J. Neurochem. 79, 200–210.
249. Tubbs R. S., Loukas M., Shoja M. M., Mortazavi M. M. and Cohen-Gadol A. A. (2011) Félix Vicq d'Azyr (1746-1794): early founder of neuroanatomy and royal French physician. Childs Nerv. Syst. 27, 1031–1034.
250. Uematsu A., Tan B. Z. and Johansen J. P. (2015) Projection specificity in heterogeneous locus coeruleus cell populations: implications for learning and memory. Learn. Mem. 22, 444–451.
251. Van Bockstaele E. J. and Valentino R. J. (2013) Neuropeptide regulation of the locus coeruleus and opiate-induced plasticity of stress responses. Adv. Pharmacol. 68, 405–420.
252. Van Dam D., Marescau B., Engelborghs S., Cremers T., Mulder J., Staufenbiel M. and De Deyn P. P. (2005) Analysis of cholinergic markers, biogenic amines, and amino acids in the CNS of two APP overexpression mouse models. Neurochem. Int. 46, 409–422.
253. Vas A. and Gulyas B. (2005) Eburnamine derivatives and the brain. Med. Res. Rev. 25, 737–757.
254. Veyrac A., Didier A., Colpaert F., Jourdan F. and Marien M. (2005) Activation of noradrenergic transmission by alpha2-adrenoceptor antagonists counteracts deafferentation-induced neuronal death and cell proliferation in the adult mouse olfactory bulb. Exp. Neurol. 194, 444–456.
255. Vijayashankar N. and Brody H. (1979) A quantitative study of the pigmented neurons in the nuclei locus coeruleus and subcoeruleus in man as related to aging. J. Neuropathol. Exp. Neurol. 38, 490–497.
256. Villela D., de Sa Lima L., Peres R., Peliciari-Garcia R. A., do Amaral F. G., Cipolla-Neto J., Scavone C. and Afeche S. C. (2014) Norepinephrine activates NF-kappaB transcription factor in cultured rat pineal gland. Life Sci. 94, 122–129.
257. Vodovotz Y., Lucia M. S., Flanders K. C. et al. (1996) Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease. J. Exp. Med. 184, 1425–1433.
258. Vollmar P., Nessler S., Kalluri S. R., Hartung H. P. and Hemmer B. (2009) The antidepressant venlafaxine ameliorates murine experimental autoimmune encephalomyelitis by suppression of pro-inflammatory cytokines. Int. J. Neuropsychopharmacol. 12, 525–536.
259. Vonck K., Raedt R., Naulaerts J., De Vogelaere F., Thiery E., Van Roost D., Aldenkamp B., Miatton M. and Boon P. (2014) Vagus nerve stimulation. 25 years later! What do we know about the effects on cognition? Neurosci. Biobehav. Rev. 45, 63–71.
260. Wade D. T., Young C. A., Chaudhuri K. R. and Davidson D. L. (2002) A randomised placebo controlled exploratory study of vitamin B-12, lofepramine, and L-phenylalanine (the “Cari Loder regime”) in the treatment of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 73, 246–249.
261. Wai M. S., Liang Y., Shi C., Cho E. Y., Kung H. F. and Yew D. T. (2009) Co-localization of hyperphosphorylated tau and caspases in the brainstem of Alzheimer's disease patients. Biogerontology 10, 457–469.
262. Wei Z., Gabriel G. G., Rui L., Cao X., Pennington P. R., Chlan-Fourney J., Nazarali A. J., Baker G. B. and Mousseau D. D. (2012) Monoamine oxidase-A physically interacts with presenilin-1(M146V) in the mouse cortex. J. Alzheimers Dis. 28, 403–422.
263. Weinshenker D. (2008) Functional consequences of locus coeruleus degeneration in Alzheimer's disease. Curr. Alzheimer Res. 5, 342–345.
264. Weintraub D., Mavandadi S., Mamikonyan E. et al. (2010) Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology 75, 448–455.
265. Wenk G. L., McGann K., Hauss-Wegrzyniak B. and Rosi S. (2003) The toxicity of tumor necrosis factor-alpha upon cholinergic neurons within the nucleus basalis and the role of norepinephrine in the regulation of inflammation: implications for Alzheimer's disease. Neuroscience 121, 719–729.
266. White S. R., Bhatnagar R. K. and Bardo M. T. (1983) Norepinephrine depletion in the spinal cord gray matter of rats with experimental allergic encephalomyelitis. J. Neurochem. 40, 1771–1773.
267. Wree A., Braak H., Schleicher A. and Zilles K. (1980) Biomathematical analysis of the neuronal loss in the aging human brain of both sexes, demonstrated in pigment preparations of the pars cerebellaris loci coerulei. Anat. Embryol. 160, 105–119.
268. Wu M. F., Gulyani S. A., Yau E., Mignot E., Phan B. and Siegel J. M. (1999) Locus coeruleus neurons: cessation of activity during cataplexy. Neuroscience 91, 1389–1399.
269. Xie L., Kang H., Xu Q. et al. (2013) Sleep drives metabolite clearance from the adult brain. Science 342, 373–377.
270. Yamamoto K., Shinba T. and Yoshii M. (2014) Psychiatric symptoms of noradrenergic dysfunction: a pathophysiological view. Psychiatry Clin. Neurosci. 68, 1–20.
271. Yang J. H., Lee E. O., Kim S. E., Suh Y. H. and Chong Y. H. (2012) Norepinephrine differentially modulates the innate inflammatory response provoked by amyloid-beta peptide via action at beta-adrenoceptors and activation of cAMP/PKA pathway in human THP-1 macrophages. Exp. Neurol. 236, 199–206.
272. Yao N., Wu Y., Zhou Y., Ju L., Liu Y., Ju R., Duan D. and Xu Q. (2015) Lesion of the locus coeruleus aggravates dopaminergic neuron degeneration by modulating microglial function in mouse models of Parkinsons disease. Brain Res. 1625, 255–274.
273. Yates C. M., Ritchie I. M., Simpson J., Maloney A. F. and Gordon A. (1981) Noradrenaline in Alzheimer-type dementia and Down syndrome. Lancet 2, 39–40.
274. Zafra F., Lindholm D., Castren E., Hartikka J. and Thoenen H. (1992) Regulation of brain-derived neurotrophic factor and nerve growth factor mRNA in primary cultures of hippocampal neurons and astrocytes. J. Neurosci. 12, 4793–4799.
275. Zarow C., Lyness S. A., Mortimer J. A. and Chui H. C. (2003) Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch. Neurol. 60, 337–341.
276. Zhang F., Kang Z., Li W., Xiao Z. and Zhou X. (2012) Roles of brain-derived neurotrophic factor/tropomyosin-related kinase B (BDNF/TrkB) signalling in Alzheimer's disease. J. Clin. Neurosci. 19, 946–949.
277. Zhang Z., Liu X., Schroeder J. P., Chan C. B., Song M., Yu S. P., Weinshenker D. and Ye K. (2014) 7,8-dihydroxyflavone prevents synaptic loss and memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 39, 638–650.
278. Zhang P., Xie M. Q., Ding Y. Q., Liao M., Qi S. S., Chen S. X., Gu Q. Q., Zhou P. and Sun C. Y. (2015) Allopregnanolone enhances the neurogenesis of midbrain dopaminergic neurons in APPswe/PSEN1 mice. Neuroscience 290, 214–226.
279. Zhou W., Li X., Huang D., Zhou W., Li T. and Song W. (2015) No significant effect of 7,8-dihydroxyflavone on APP processing and Alzheimer-associated phenotypes. Curr. Alzheimer Res. 12, 47–52.
280. Zhu M. Y., Wang W. P., Iyo A. H., Ordway G. A. and Kim K. S. (2005) Age-associated changes in mRNA levels of Phox2, norepinephrine transporter and dopamine beta-hydroxylase in the locus coeruleus and adrenal glands of rats. J. Neurochem. 94, 828–838.
281. Zhu Y., Fenik P., Zhan G., Xin R. and Veasey S. C. (2015) Degeneration in arousal neurons in chronic sleep disruption modeling sleep apnea. Front. Neurol. 6, 109.
282. Zoghbi H. Y., Milstien S., Butler I. J., Smith E. O., Kaufman S., Glaze D. G. and Percy A. K. (1989) Cerebrospinal fluid biogenic amines and biopterin in Rett syndrome. Ann. Neurol. 25, 56–60.
283. Zoukos Y., Leonard J. P., Thomaides T., Thompson A. J. and Cuzner M. L. (1992) beta-Adrenergic receptor density and function of peripheral blood mononuclear cells are increased in multiple sclerosis: a regulatory role for cortisol and interleukin-1. Ann. Neurol. 31, 657–662.
284. Zweig R. M., Ross C. A., Hedreen J. C., Peyser C., Cardillo J. E., Folstein S. E. and Price D. L. (1992) Locus coeruleus involvement in Huntington's disease. Arch. Neurol. 49, 152–156.
285. Zyzek E., Richard F., Bouilloux J. P. and Pujol J. F. (1990) Ontogeny of tyrosine hydroxylase concentration in locus coeruleus of newborn rats: long-term effects of RU24722. J. Neurochem. 55, 849–853.